Decrease In California’s STIs Followed Early Real-World Adoption Of doxyPEP, Research Suggests

MedPage Today (1/6, Lou) reports research found that “a decrease in California’s sexually transmitted infections (STIs) followed early real-world adoption of doxycycline post-exposure prophylaxis (doxyPEP), suggesting real population-level benefits to this public health strategy.” Study results indicate that “in San Francisco, cases of chlamydia and early syphilis fell steadily and were roughly halved at the 13-month mark after implementation of doxyPEP in the city, one report showed, while at Kaiser Permanente Northern California, incident chlamydia and certain types of site-specific gonorrhea were significantly reduced among doxyPEP user- versus nonuser-members.” The two studies’ findings were published in JAMA Internal Medicine, and can be found here and here.